Acerus to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference

Acerus Pharmaceuticals Corporation (TSX:ASP) announced today that Edward Gudaitis, President and Chief Executive Officer of Acerus, is scheduled to present an overview of the company at the Bloom Burton & Co. Healthcare Investor Conference. Mr. Gudaitis’ address will take place at the Metro Toronto Convention Centre, 255 Front Street W, Toronto, Ontario on May 1, 2019 at 10:00 a.m. Eastern Time.

The presentation will be webcast live. To access the webcast, please visit http://wsw.com/webcast/bloomburton4/asp.to/. The webcast replay will remain available on the company’s website, www.aceruspharma.com for 90 days following the live presentation.

About the conference

The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and International investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings.

About Acerus Pharmaceuticals Corporation

Acerus Pharmaceuticals Corporation is a Canadian-based specialty pharmaceutical company focused on the development, manufacture, marketing and distribution of innovative, branded products that improve patient experience, with a primary focus in the field of men’s and women’s health. The Company commercializes its products via its own salesforce in Canada, and through a global network of licensed distributors in the U.S. and other territories.

Acerus’ shares trade on TSX under the symbol ASP. For more information, visit www.aceruspharma.com and follow us on Twitter and LinkedIn.

Forward-Looking Information

Information in this press release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information are assumptions regarding our future operational results. These assumptions, although considered reasonable by the company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the company is subject to a number of risks and uncertainties, and could differ materially from what is currently expected as set out above. For more exhaustive information on these risks and uncertainties you should refer to our annual information form dated March 4, 2019 that is available at www.sedar.com. Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190424005157/en/

Robert Motz
Chief Financial Officer
Acerus Pharmaceuticals Corporation
[email protected]
(905) 817-8288